Axial Spondyloarthritis - Pipeline Review, H1 2018

  • ID: 4537869
  • Report
  • 107 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Eli Lilly and Co
  • Fresenius SE & Co KGaA
  • Novartis AG
  • Sandoz International GmbH
  • UCB SA
  • MORE
Axial Spondyloarthritis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Axial Spondyloarthritis - Pipeline Review, H1 2018, provides an overview of the Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline landscape.

Axial spondylitis is a type of inflammatory arthritis involving the spine and/or sacroiliac joints. Axial spondylitis is strongly related to the presence of the HLA-B27 gene. A genetic test for HLA-B27 is available.

Report Highlights:

This latest pipeline guide Axial Spondyloarthritis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Axial Spondyloarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Discovery stages are 2, 4, 1 and 1 respectively.

Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Axial Spondyloarthritis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Eli Lilly and Co
  • Fresenius SE & Co KGaA
  • Novartis AG
  • Sandoz International GmbH
  • UCB SA
  • MORE
Introduction

Report Coverage

Axial Spondyloarthritis - Overview

Axial Spondyloarthritis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Axial Spondyloarthritis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Axial Spondyloarthritis - Companies Involved in Therapeutics Development

AstraZeneca Plc

Eli Lilly and Co

Fresenius SE & Co KGaA

Novartis AG

Sandoz International GmbH

Sun Pharma Advanced Research Company Ltd

UCB SA

Axial Spondyloarthritis - Drug Profiles

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brodalumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

certolizumab pegol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ixekizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

secukinumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tildrakizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Axial Spondyloarthritis - Dormant Projects

Axial Spondyloarthritis - Product Development Milestones

Featured News & Press Releases

Feb 13, 2018: Lilly Announces Positive Top-Line Phase 3 Results for Taltz (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

Jun 14, 2017: Results from CRIB study on CIMZIA (certolizumab pegol) demonstrate minimal to no placental transfer of drug from mother to infant during third trimester of pregnancy

Jun 14, 2017: UCB announces four-year imaging results demonstrating low disease progression and long-term efficacy of CIMZIA (certolizumab pegol) in patients with axial spondyloarthritis

Apr 24, 2017: Kyowa Hakko Kirin Announces Initiation of Global Phase 3 Study of KHK4827 (Brodalumab) in Patients with Axial Spondyloarthritis (axSpA)

Mar 06, 2017: First CIMZIA Study of Its Kind Showed Minimal to No Transfer of Drug from Mother’s Plasma to Breast Milk

Nov 11, 2016: UCB Presents Data on Cimzia (certolizumab pegol) at 2016 ACR/ARHP Annual Meeting

Oct 25, 2016: Certolizumab pegol (Cimzia) AutoClicks Prefilled Pen - a New Self-injection Device Designed in Collaboration With Patients and Good Grips - is Now Available in the UK on the NHS

Jun 08, 2016: UCB commitment to addressing real world patient needs on display at the Annual European Congress of Rheumatology (EULAR 2016)

Nov 06, 2015: UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting

Nov 14, 2014: UCB Shows Strong Scientific Presence On Certolizumab pegol (CIMZIA) At Leading Rheumatology Meeting

Sep 20, 2013: UCB receives CHMP positive opinion for Cimzia in severe active axial spondyloarthritis

Jul 24, 2013: U.S. FDA Arthritis Advisory Committee Votes On Cimzia For Treatment of Adults with Active Axial Spondyloarthritis, Including Patients with Ankylosing Spondylitis

Jun 14, 2013: UCB's Certolizumab Pegol Rapidly Improves Pain, Fatigue And Physical Function In axSpA Patients In Phase III Study

Feb 20, 2013: UCB Announces Regulatory Filings For Cimzia To Treat Psoriatic Arthritis And Axial Spondyloarthritis

Nov 13, 2012: UCB Announces Presentation Of Phase III Trial Results Of Certolizumab Pegol In Axial Spondyloarthritis At ACR 2012 Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Axial Spondyloarthritis, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Axial Spondyloarthritis - Pipeline by AstraZeneca Plc, H1 2018

Axial Spondyloarthritis - Pipeline by Eli Lilly and Co, H1 2018

Axial Spondyloarthritis - Pipeline by Fresenius SE & Co KGaA, H1 2018

Axial Spondyloarthritis - Pipeline by Novartis AG, H1 2018

Axial Spondyloarthritis - Pipeline by Sandoz International GmbH, H1 2018

Axial Spondyloarthritis - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018

Axial Spondyloarthritis - Pipeline by UCB SA, H1 2018

Axial Spondyloarthritis - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Axial Spondyloarthritis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AstraZeneca Plc
  • Eli Lilly and Co
  • Fresenius SE & Co KGaA
  • Novartis AG
  • Sandoz International GmbH
  • Sun Pharma Advanced Research Company Ltd
  • UCB SA
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll